Obesity Treatment DevelopmentThe new development candidate PN-477 for obesity is expected to be highly competitive due to its engineered receptor binding and strong lean mass preservation.
Psoriasis Study ResultsPTGX and partner JNJ announced positive data from the two Ph3 ICONIC ADVANCE 1&2 studies that compared icotrokinra (JNJ-2113) vs. deucravacitinib (Sotyktu) head-to-head, showing statistical superiority to Sotyktu at Weeks 16 and 24.
Psoriasis Treatment EfficacyIcotrokinra is expected to emerge as the preferred oral treatment option in psoriasis due to its mix of efficacy and safety.